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BACKGROUND: Although the naturally occurring reovirus causes only mild symptoms in humans, it shows considerable potential as an
oncolytic agent because of its innate ability to target cancer cells. In immunocompromised hosts, however, wild-type reovirus can
target healthy tissues, including heart, liver, pancreas and neural structures.
METHODS: We characterized an attenuated form of reovirus (AV) derived from a persistently infected cell line through sequence
analysis, as well as western blot and in vitro transcription and translation techniques. To examine its pathogenesis and oncolytic
potential, AV reovirus was tested on healthy embryonic stem cells, various non-transformed and transformed cell lines, and in severe
combined immunodeficiency (SCID) mice with tumour xenografts.
RESULTS: Sequence analysis of AV reovirus revealed a premature STOP codon in its sigma 1 attachment protein. Western blot and
in vitro translation confirmed the presence of a truncated s1. In comparison to wild-type reovirus, AV reovirus did not kill healthy
stem cells or induce black tail formation in SCID mice. However, it did retain its ability to target cancer cells and reduce tumour size.
CONCLUSION: Despite containing a truncated attachment protein, AV reovirus still preferentially targets cancer cells, and compared
with wild-type reovirus it shows reduced toxicity when administered to immunodeficient hosts, suggesting the potential use of AV
reovirus in combination cancer therapy.
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Mammalian REO (respiratory enteric orphan) virus is a small,
non-enveloped icosahedral virus that contains segments of
double-stranded RNA as its genome. In humans, reovirus targets
the upper respiratory and gastrointestinal tracts to generate a
relatively benign and often asymptomatic infection (Tyler, 2001).
Of interest is its ability to infect and kill many types of trans-
formed cells (Hashiro et al, 1977; Duncan et al, 1978), making
reovirus one example among a variety of replication competent
oncolytic viruses that potentially serve as anti-cancer therapies.
Such oncolytic viruses have, in principle, two main advantages
over conventional chemotherapy and radiotherapy. First, they
generally target cancer cells because of their reduced ability,
whether innate or engineered, to replicate in normal cells. Second,
in comparison with replication-incompetent vectors, they can
propagate from initially infected cancer cells to surrounding or
distant cancer cells, thereby achieving a large volume of
distribution and potent anti-cancer effects. Despite the above,
ongoing challenges in this field include, ensuring that (a) all
cancer cells are efficiently targeted, including those that have
metastasised to distant sites; (b) damage to normal tissues and
proliferating cells is minimized and (c) natural host-immune
responses do not prematurely block viral eradication of tumour
cell populations.
Reovirus Type 3 Dearing (T3D) is a naturally occurring
oncolytic virus that preferentially targets Ras-transformed cells
both in vitro and in vivo (Coffey et al, 1998; Strong et al, 1998;
Norman et al, 2004). Constitutively activated Ras contributes to
reovirus oncolysis by increasing the efficiency of (1) reovirus
disassembly during entry, (2) infectious virion production and
(3) apoptosis and virion release (Marcato et al, 2007). As Ras gene
mutations are observed in over 30% of all human cancers
(Duursma and Agami, 2003), these findings have led to the
current use of reovirus in phase I, II and III clinical trials
(Oncolytics Biotech Inc., 2010). However, in immunocompromised
hosts, such as newborn and severe combined immunodeficiency
(SCID) animals; wild-type reovirus shows significant patho-
genicity, especially to neural and cardiac muscle tissues (Sabin,
1959; Weiner et al, 1977; Baty and Sherry, 1993; Loken et al, 2004).
Occasionally, this pathogenesis is observed in immunocompetent
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shosts, but mainly at high viral loads (Hirasawa et al, 2003;
Terheggen et al, 2003). Clinical trials have reported no severe
toxicity when utilising wild-type reovirus in combination with
radiation or chemotherapy (Thirukkumaran and Morris, 2009).
Even so, a less virulent reovirus that displays reduced patho-
genicity to healthy tissues and cells while retaining potent
oncolytic activity could still be beneficial by providing a potentially
higher number of treatments or dosage.
One way of generating less virulent reovirus is through the
establishment of persistently infected cells. Persistent reovirus
infection is occasionally induced in various cell types in vitro
(Dermody, 1998). Although the underlying basis of reovirus
persistent infection is not well understood, it has been speculated
that interactions between the virus and host cell can be
fundamentally altered such that a modified cytopathic virus–host
relationship is established (Wetzel et al, 1997). Importantly, such
infections can give rise to distinct reovirus variants (Ahmed and
Fields, 1982; Wilson et al, 1996; Wetzel et al, 1997); however,
the potential utility of these variants for reovirus oncolysis has
yet to be examined. In this report, we describe a mutant reovirus
with a modified S1 gene that has been isolated from persis-
tently infected cells. The modified reovirus contains a truncated
s1-cell-attachment protein and displays significantly reduced
pathogenic potential to healthy cells while maintaining its
oncolytic activity. This attenuated virus (AV) may provide a
desirable option in future oncolytic cancer therapy.
MATERIALS AND METHODS
Cell lines
HT1080 human fibrosarcoma, L929 murine fibrosarcoma, Raji
human Burkitt’s lymphoma, CA46 human Burkitt’s lymphoma and
HEK 293 cell lines were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and were
maintained according to the ATCC protocols. To establish
persistently infected cell lines, HT1080, Raji and CA46 cells were
infected with wild-type (WT) reovirus at a multiplicity of infection
(MOI) of 20. The surviving cells were maintained for 3–10 weeks
until they reached confluency and subsequently reinfected 2–3
times for up to 3–7 weeks to ensure the selection of virus-resistant
cells (Ahmed and Fields, 1982). From the surviving cells of
HT1080, several subclones were obtained by serial dilution. Clone
HTR1 (HT1080 virally resistant clone 1) was used for this study.
HTR1 cells were persistently infected and maintained for more
than 48 months (Kim et al, 2007). From surviving Raji and CA46
cells, persistently infected Raji PI (Alain et al, 2006), and CA46 PI
were stably established and maintained for more than 6 months.
Murine R1 and D3 embryonic stem cell lines were also
purchased from the ATCC. The cells were maintained in high
glucose DMEM, 15% FCS (selected batches), 50Uml
 1 penicillin
and 50mgml
 1 streptomycin, 1% nonessential amino acids and
0.1mM b-mercaptoethanol as described (zur Nieden et al, 2001).
Pluripotency was sustained by adding 1000Uml
 1 leukaemia
inhibitory factor (LIF) to the culture. The cultures were passaged at
80% confluency approximately every second day. All medium
components were purchased from Invitrogen (Burlington, ON,
Canada). Murine MES1 embryonic stem cells were isolated from
3.5-day postcoitum embryos of the 129 IM/SvJ substrain at the
blastocyst stage. MES1 were routinely grown as described for
R1 and D3 ESCs.
Reovirus propagation, titration and infection
The wild-type reovirus T3D strain used in this study was propagated
in L929 cells and purified by cesium chloride ultracentrifugation as
described previously (Smith et al, 1969). Attenuated reovirus
derived from the HTR1 culture was purified by the same method
used in wild-type reovirus preparation, except AV reovirus was
propagated in HT1080 and L929 cells. For AV reovirus collection
from HT1080- and HTR1-infected supernatants (used only in
Figure 2B), high-speed ultracentrifugation at 35000r.p.m. was used
to pellet the virus.
For wild-type reovirus titration, HEK 293 cells were plated in
6-well plates at 2 10
5 cells per well. After 2h of adsorption at 371C,
the inoculum was removed. Cell monolayers were then covered with
1% agar and fresh medium. Plaques were counted 5–7 days after
infection. For AV reovirus titration, the same procedure was
followed except after 5–7 days of infection, the agar was removed
and cell monolayers were fixed/permeabilzed with cytofix/cytoperm
(BD Biosciences, Mississauga, ON, Canada) for immunostaining
with reovirus antiserum and secondary FITC antibody. Attenuated
reovirus plaques were identified by immunofluorescence detection.
Furthermore, WT and AV reovirus titrations were also performed
on monolayers of L929 cells, which after an initial infection for 1h at
371C, were subsequently covered with a 1:1 ratio of 1% agar and 2X
MEM containing 10% horse serum. Plaques were counted 5–7 days
after infection using a neutral red counterstain. In either case, titers
yielded PFU:particle ratios of approximately 1:200 for both WT and
AV reovirus, respectively.
Cells were infected with reovirus (MOI of 20 or 40) in serum-free
media and after 1h the virus-containing media was replaced with
the appropriate cell-culture media.
Sequencing of reovirus S1 and S4 genes
Viral dsRNAs, derived from WT reovirus and Raji, CA46 and
HTR1 persistent reovirus infected cells were TRIzol extracted,
converted to cDNA by reverse transcription, and PCR amplified.
The PCR reactions were hot-started (held at 941C for 30s),
followed by 35 cycles of 1min at 941C, 1min at 591C and 1min 30s
at 721C. A final extension for 10min at 721C was performed and
the reaction product was cooled to 41C. The primers used to
amplify the S1 gene segment were 50-CATGAATTCATGGATCC TC
GCCTACGTTAAGAAG-30 (Forward) and 50-CAGAAGCTTCTGAT
CCTCACGTGAA ACTACGC-30 (Reverse), and the primers used to
amplify the S4 gene segment were 50-CAAGAATTCTTGTCGCAAT
GGAGGTGTG-30 (Forward) and 50-TCTAAGCTTAGATG GGGGTG
TTTAGCCAAG-30 (Reverse). Sequencing results were obtained
from the University of Calgary Core DNA services. The sequence
that was established, including the premature stop codon in the
S1 gene (Table 1), has remained stable for 3 years of culture since
the AV virus was first isolated from HTR1 cells.
Immunoblot, radiolabelling, FACS and electron
microscopy
Cell lysates were prepared by sonication in a buffer containing
10mM Tris (pH 7.4), 2mM EDTA, 1% NP-40, 50mM mercapto-
ethanol, 100mgml
 1 leupeptin and 2mgml
 1 aprotinin. The lysates
were then cleared by centrifugation at 16000g for 15min,
normalised for protein amount, mixed with SDS sample buffer,
boiled for 5min and stored at  701C. After separation by
SDS–PAGE, proteins were transferred to nitrocellulose or
PVDF membranes and detected by immunoblot hybridisation.
The primary antibodies (Abs) used were: anti-reovirus polyclonal
Ab (Strong et al, 1998) and anti-s1 N-terminus monoclonal
Ab (Duncan and Lee, 1994). Horseradish peroxidase-conjugated
anti-mouse Ab or horseradish peroxidase-conjugated anti-rabbit
Ab were used as secondary Abs (Pierce Biotechnology, Rockford,
IL, USA).
For metabolic labelling, [
35S]-methionine was added to the
culture medium for 12h. Cells were harvested and lysed
in PBS buffer containing 1% Triton X-100, 0.5% sodium
deoxycholate and 1mM EDTA. Lysates were cleared of debris
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sby centrifugation and supernatants were stored at  701C until
use. Polyclonal rabbit anti-reovirus serotype 3 serum was
used for immunoprecipitation of [
35S]-methionine-labelled
reovirus proteins from cell lysates as described previously
(Lee et al, 1981). Immunoprecipitated proteins were subjected to
SDS–PAGE, followed by autoradiography.
For flow cytometry analysis, cells were trypsinized and fixed
using cytofix/cytoperm solution (PharMingen, San Diego, CA,
USA). The fixed and permeabilized cells were incubated with
primary reovirus antiserum and secondary FITC-conjugated
anti-rabbit IgG (Cedarlane, Burlington, ON, Canada), then
analysed by flow cytometry.
In vitro transcription and translation
Trizol was used to extract dsRNA from purified AV reovirus. The
resulting RNA underwent cDNA synthesis using the S1 gene-specific
primer (50-GATGAAATGCCCCAGTGCCGC-30) and the conditions
for SuperScript II reverse transcriptase (Invitrogen). The cDNA was
used as template for PCR amplification of AV reovirus S1. Using
primers 50-AGGAATTCGCTATTGGTCGGA-30 (Forward) and 50-GC
TAGCTAGAGCGGCCGCGATGAAAT-30 (Reverse), AccuPrime Pfx
DNA polymerase (Invitrogen), and an annealing temperature of
55C, the S1 open reading frame was amplified with EcoR1 and
Not1 restriction enzyme overhangs. The S1 PCR product was
PCR purified (Invitrogen) and double-digested at 371Cf o r2 h
along with vector, pcDNA3 (Invitrogen), using restriction enzymes
EcoR1 and Not1 (NEB, Pickering, ON, Canada). Digested products
were gel purified (Invitrogen) and then ligated (Invitrogen) at room
temperature for 1h. The AV reovirus S1 plasmid was transformed
into Top10 Escherichia coli-competent cells and screened by
ampicillin resistance. Individual bacterial colonies were inoculated
into ampicillin LB broth, midi-prepped (Invitrogen) and analysed
for incorporation of the S1 insert.
Using the AV reovirus S1 plasmid as template, the AV S1 open
reading frame was amplified by Taq DNA polymerase (Invitrogen)
at an annealing temperature of 551C using the primers 50-GGTA
CCTAATACGACTCACTATAGGGGCTATTGCCACC-30 (Forward)
and 50-GATGAAATGCCCCAGTGCCGC-30 (Reverse), which were
optimised for T7 transcription. The S1 PCR product was gel
purified (Invitrogen) and eluted using 10mM Tris pH 8.0. In vitro
transcription was performed using a 50ml reaction containing
5mg of AV reovirus S1 template by the RiboMAX large-scale
RNA production systems for T7 polymerase (Promega, Nepean,
ON, Canada). The transcription reaction was treated with DNase
(Promega) for 10min at 371C to remove any residual DNA
template, RNA purified (Qiagen, Mississauga, ON, Canada), and
then analysed by RNase-free agarose gel electrophoresis. The
AV reovirus S1 RNA transcript was translated using a 25ml
reaction from the rabbit reticulocyte lysate system (Promega). The
samples were analysed by 12% SDS–PAGE and subsequent
autoradiography.
Animal studies
Severe combined immunodeficiency mice (Charles River,
Wilmington, MA, USA) received a single subcutaneous implanta-
tion of 5 10
6 cells of murine ESCs (R1 or MES1). At 12 days after
implantation, palpable teratomas were observed. The R1 teratomas
were then injected with reoviruses (WT reo (wild-type reovirus),
1 10
7 PFU/tumour; n¼5, AV reo (AV reovirus), 1 10
7 PFU/
tumour: n¼5, D reo (Dead, UV-inactivated reovirus): n¼5) and
teratoma growth was followed 21–70 days post-infection. For the
MES1 teratoma experiment, 12–15 days after implantation,
teratomas were intratumourally injected with reoviruses or PBS
(WT Reo (wild-type reovirus, 10
7 PFU per mouse); n¼3, AV Reo
(AV reovirus, 10
7 PFU per mouse): n¼3, PBS: n¼3) and
teratoma growth was followed 31–46 days post-infection.
Each SCID mouse received single subcutaneous implantations of
5 10
6 cells of HT1080 or HCT116 cells suspended in PBS. At
11 days after implantation, 4–6 mice with tumours were injected
intratumourally with WT, AV or D (Dead, UV-inactivated)
reovirus at 10
7 PFU/tumour and tumour growth was followed up
to 34 days post implantation. WT reovirus was reinjected after
23 days post implantation and AV reovirus was reinjected after
23 and 27 days.
All the mice were treated according to the protocols approved by
the University of Calgary Animal Care Committee. Tumour growth
was measured externally using calipers and the volume was
determined by the equation V¼(L W
2) 0.5, where L is the
largest dimension and W is the largest dimension perpendicular
to L. Tumours and hearts were taken from the mice at 34–35 days
post implantation and fixed in 10% buffered formalin solution at
room temperature, then paraffin embedded. Teratomas were taken
from the mice at 21–70 days post-infection, excised and fixed in
10% buffered formalin solution at room temperature. The speci-
mens were processed by the University of Calgary Histopathology
Laboratory Research Service for routine histological analysis
(H&E staining).
Histology and Immunohistochemistry
For reovirus antigen detection (reovirus structural proteins),
deparaffinized tumour sections were retrieved in a solution
containing 50mM Tris (pH 7.5), 120mM NaCl, 0.2% Tween 20
and 0.1% Triton X-100. After blocking the sections with a solution
containing 50mM Tris (pH 7.5), 120mM NaCl, 0.2% Tween 20,
0.1% Triton X-100 and 2% normal goat serum for 1h, the sections
were immunostained with a solution containing 0.1% reovirus
antiserum, 50mM Tris (pH 7.5), 120mM NaCl, 0.2% Tween 20,
0.1% Triton X-100 and 2% normal goat serum for 2h. As a
secondary antibody, biotinylated goat anti-mouse antibody
(Vector Laboratories, Burlingame, CA, USA) was used at 1:100
in a solution containing 50mM Tris (pH 7.5), 120mM NaCl,
Table 1 S1 and S4 gene mutations of persistently infecting reoviruses
Mutation position
Persistent
reovirus
Reovirus
gene Nucleotide
Amino
acid
GenBank
accession no.
HTR1 S1 359, T–C 116, L–P AY860061
392, T–C 127, V–A
763, C–T 251, Q–Stop
912, A–G 300, I–M
S4 562, C–T 177, S–F DQ915165
784, A–T 251, H–L
CA46 PI S1 89, A–C 26, K–T EF133509
7, K–Q
1351, A–T 447, T–S
S4 720, C–T 230, H–Y EF133510
730, C–T 233, S–L
1089, A–C 353, N–Q
1091, T–G 353, N–Q
1092, T–C 354, Y–H
Raji PI S1 — — EF133511
S4 784, A–T 251, H–L EF133512
Mutations in S1 and S4 gene nucleotide sequences of persistently infecting reoviruses
from HTR1, Raji PI and CA46 PI cells, and corresponding mutations in the deduced
amino acid sequences of their gene products (S1: s1/s1s, S4: s3) compared with
previously published sequences of WT reovirus (GenBank accession no: S1
(X01161), S4 (K02739)). As reovirus occasionally undergoes spontaneous genome
variations, nucleotide changes that were found in all the persistently infecting
reoviruses and in our lab, WT reovirus were not included in this table (S1: 366, C–G,
367, G–C, S4: 624, G–A, 719, G–T).
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s0.2% Tween 20, 0.1% Triton X-100 and 2% normal goat serum
for 2h at room temperature. Detection was monitored by a
diaminobenzidine tetrahydrochloride-based immunohistochemis-
try protocol according to the manufacturer (Vector Laboratories).
Dehydration was carried out in a series of graded ethanol
solutions, followed by clarification in xylene. Slides were mounted
with Vectamount (Vector Laboratories) and stored at 251C.
RESULTS
Persistent reovirus infection of cultured cells gives rise to
reovirus variants
Our group recently reported that persistent reovirus infections
could be established in oncogenic N-Ras human fibrosarcoma
HT1080 cells and p53 mutated lymphoma cells, yielding persis-
tently infected (PI) HTR1 (Kim et al, 2007) and Raji PI (Alain et al,
2006) cells, respectively. In this study, we have also included a
newly established persistent reovirus infection from the Burkitt’s
lymphoma cell line CA46 (p53 mutated). As shown in Figure 1,
infected parental cells exhibited abundant reovirus protein
synthesis, whereas PI derivatives showed viral proteins (l, m and
s classes) even without the addition of wild-type reovirus.
Furthermore, the viral protein expression profile in the PI cells
was similar to that of the newly infected parental cells.
AV reovirus produces a truncated r1 protein
Virus preparations from each of the infected cell lines were
analysed for genetic modifications. As alterations of the S1 and S4
genes have a role in persistently infected L cells (Ahmed and
Fields, 1982; Wetzel et al, 1997), gene segments from HTR1, Raji PI
and CA46 PI-derived reoviruses were sequenced. As shown in
Table 1, multiple mutations of S1 and S4 genes were detected.
Surprisingly, the S1 gene of the HTR1-derived virus contained a
stop codon mutation at amino acid 251 in the S1 gene product (cell
attachment protein s1). s1 is responsible for binding host cell
receptors, including primary receptor sialic acid and various
secondary receptor proteins (Lee et al, 1981; Chappell et al, 1997;
Barton et al, 2001).
Immunoblotting of the HTR1-derived reovirus and WT reovirus
using a polyclonal anti-reovirus antibody and a polyclonal anti-s1
antibody (raised against the N-terminus) revealed the presence
of a 25kD protein in the reovirus variant; a protein product
approximately half the size of its full-length, 455 amino-acid form
(Figure 2A). HT1080 cells infected with the HTR1 reovirus variant
were also found to express the truncated s1 protein (Figure 2B).
HT1080 HTR1 Raji Raji PI CA46 CA46 PI
Reo Reo Reo









– –+ +– –+ +– –+ +
Figure 1 Persistent infection of reovirus in various cancer cells. HT1080, Raji and CA46 cells and their persistently infected derivatives were infected with
wild-type reovirus (MOI of 40) and labelled with [
35S]-methionine at 3 hpi for 12h. At 24 hpi, cells were lysed, immunoprecipitated with anti-reovirus
antibodies, and subjected to SDS–PAGE and autoradiography. Reovirus protein classes are indicated by l, m and s.
AV A
BC
75 kDa
75 kDa
WT-1
WT-1
AV-1
AV-1
50 kDa
50 kDa
37 kDa
37 kDa
25 kDa
25 kDa
Anti-reovirus
Anti-reovirus
HT1080 - AV
HT1080 - AV
HTR1
HTR1
WT
WT
Anti-1N
Anti-1N
AV-1
Luc
Luc (–)RNA
AV WT WT
Figure 2 AV reovirus possesses a truncated s1 protein. (A) WT and
AV reovirus were purified from L929 murine fibroblasts and examined for
the presence of s1. Through immunoblotting, membranes were probed
with reovirus antiserum (left panel) and polyclonal reovirus s1 N-terminus
antiserum (right panel). The N-terminal antibody was raised against s1
amino acids 1–158 (Duncan and Lee, 1994). (B) Attenuated reovirus was
collected from infected HT1080 and PI HTR1 supernatants by high-speed
ultracentrifugation and examined by immunoblotting using reovirus
antiserum (left panel) and polyclonal s1 N-terminus antiserum (right
panel). Purified WT reovirus was used as a point of reference. (C) In vitro
transcription of the AV reovirus S1 gene by T7 polymerase produced a s1
RNA transcript that was in vitro translated using a rabbit reticulocyte system.
Translation of a luciferase transcript and a minus RNA reaction were used
as positive and negative controls, respectively. The samples were analysed
by 12% SDS–PAGE and subsequent autoradiography.
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sFurthermore, in vitro transcription and translation of the cloned
S1 gene from the HTR1-derived virus also generated a truncated
25kD s1 protein (Figure 2C). Collectively, these results confirm
that the PI HTR1-derived reovirus variant produces a truncated
s1 protein representing the N-terminal half of the full-length
s1 protein and from which the C-terminal portion (which is active
in cell adhesion; Weiner et al, 1977; Wilson et al, 1996; Wetzel
et al, 1997) is absent. The virus variant was accordingly referred to
as AV reovirus.
AV reovirus spares the developmental potential of normal
mESCs
In addition to causing various pathogenic manifestations in
immunodeficient hosts, WT reovirus is also known to rapidly
target normal ESCs and adversely affect the formation of rat
and mouse blastocysts; thus inhibiting embryonic development
(Heggie and Gaddis, 1979; Priscott, 1983). To determine if the
attenuated virus was capable of inducing cytopathogenicity
in ESCs, two murine ESC lines (R1 and D3) were infected with
either AV or WT reovirus. In comparison with the WT virus,
immunoblot and flow cytometry analyses revealed minimal
infectivity of ESCs by AV reovirus and reduced viral protein
synthesis by 48h post-infection (Figure 3A). In addition, AV
reovirus infected R1 and D3 ESCs showed no detectable signs of
viral cytopathogenicity, whereas WT reovirus induced extensive
cytopathic effects and the destruction of embryoid bodies
(Figure 3B). To compare AV and WT reovirus pathogenesis
in vivo, a murine teratoma model was adopted, in which pluri-
potent ESCs were able to develop into mature benign teratomas
with a high level of differentiation upon xenograft implantation
in vivo (Sasaki et al, 2005). Thus, SCID mice were xenografted with
murine R1 or MES1 ESCs and teratomas were allowed to develop
into palpable tumours. At 12 days post implantation, AV or WT
reoviruses were delivered intratumourally and benign teratoma
growth was monitored (Figure 3C). Photographs of representative
R1 teratomas were taken 9 days after reovirus administration
(21 days after implantation) (Figure 3D). Consistent with the
in vitro observations, AV reovirus did not suppress benign
teratoma growth or differentiation, whereas WT reovirus pre-
vented further teratoma growth and induced neuroglia necroses
(histological data not shown), supporting previous findings that
WT reovirus targets the nervous system in suckling mice (Flamand
et al, 1991; Oberhaus et al, 1997). Therefore, unlike WT reovirus,
AV reovirus exhibits a reduced cytopathogenicity towards various
non-cancerous and differentiated cell types.
AV reovirus retains oncolytic activity in vitro
As the S1 gene of reovirus has a critical role in binding host
cells and in virus-induced apoptosis (Lee et al, 1981; Duncan
et al, 1991; Tyler et al, 1995; Connolly et al, 2001), we speculated
that the oncolytic activity of AV reovirus would be somewhat
reduced. To determine if AV reovirus mimicked the wild-type
form by preferentially targeting Ras-transformed cells, N-Ras-
transformed HT1080 fibrosarcoma cells and K-Ras-transformed
HCT116 colon carcinoma cells were challenged with the virus.
Attenuated reovirus retained its ability to kill parental HT1080
cells efficiently in vitro, however its pathogenesis on L929 and
HCT116 cells was somewhat reduced (Figure 4B). Cytopathic
effects on L929 cells by AV reovirus were observed by 72 hpi (data
not shown). Attenuated reovirus protein synthesis remained
comparable or slightly decreased compared with the WT virus,
suggesting that the cytolytic activity of AV reovirus had been
partially attenuated (Figure 4B). Furthermore, our group recently
showed that cancer cells dysfunctional in p53, ATM or Rb, are
susceptible to both WT and AV reovirus (Kim et al, 2010). Thus,
although the cytocidal potency of AV reovirus in vitro is somewhat
reduced, it retains its ability to infect and replicate in a variety of
tumour cell types.
AV reovirus displays reduced host toxicity while retaining
its oncolytic activity in vivo
Even though WT reovirus infection is often asymptomatic or
causes only mild disease in immunocompetent hosts, it can induce
various pathologic manifestations, such as myocarditis, vasculitis,
black tail syndrome and neuronal damage in newborn and
immunodeficient animals (Sabin, 1959; Weiner et al, 1977; Baty
and Sherry, 1993; Terheggen et al, 2003; DeBiasi et al, 2004; Loken
et al, 2004). Genetic reassortment studies of reovirus genes have
implicated S1 in having a significant role in determining reovirus
pathogenesis (Weiner et al, 1977, 1980; Haller et al, 1995). As the
replication competent AV reovirus is mutated in the S1 gene,
produces a truncated s1 protein, and exhibits reduced cytolytic
potential in vitro, its capacity for oncolysis and pathogenesis
in vivo was also assessed.
We first compared the AV reovirus producing cell line, HTR1,
with two other reovirus persistently infected cells lines (Raji PI and
CA46 PI) for their respective pathogenicities in reovirus-susceptible
SCID mice (George et al, 1990; Loken et al, 2004). Previously, we
showed that persistently infected cells lose tumourigenicity in vivo
(Alain et al, 2006; Kim et al, 2007), and as expected, none of the three
persistently infected cell lines were able to produce tumours in SCID
mice. Nevertheless, mice injected with Raji PI or CA46 PI cells
rapidly developed black tail syndrome (Figure 5A) and displayed
severe morbidity by 3–4 weeks post-inoculation. In contrast, HTR1
inoculated mice showed no visible morbidity after 1 month and only
began to develop black tail syndrome after 3–7 months.
To assess the oncolytic potential of AV reovirus in vivo, human
Ras-oncogenic HCT116 colon carcinoma cells or HT1080 fibro-
sarcoma cells were implanted in SCID mice and subsequently
treated with reovirus. During the first 23 days of virus treatment, it
was found that both WT and AV reovirus effectively suppressed
tumour growth, whereas inactivated virus (D reo) showed no
suppression of tumour growth (Figure 5B). At this point, it was
clear that tumour suppression by AV or WT reovirus was
comparable, however, it did not address the issue of host
cytotoxicity and as a result, longer-term studies were required.
As current clinical trials utilise multiple reovirus administrations,
AV reovirus was reinjected two more times at day 23 and 27 into
the established SCID mice tumours. Wild-type reovirus was also
reinjected at day 23, but not at day 27 because of increased host
cytotoxicity. This is consistent with previous studies that have
already shown that a single injection of the WT virus is enough to
cause black tail syndrome in SCID mice (Loken et al, 2004).
Ultimately, mice treated with WT reovirus were all killed at 25–40
days post-viral inoculation because of severe morbidity (weight
loss and black tail development), whereas mice treated with AV
reovirus only developed these pathologies after several months
post-treatment. Immunohistochemical analysis revealed that both
WT and AV reovirus replicated well at tumour sites (Figure 5C).
As WT reovirus is known to cause myocarditis (Baty and Sherry,
1993; Terheggen et al, 2003), heart tissue was examined by
hematoxylin and eosin staining, and analysed by immunohisto-
chemistry. Mice treated with WT reovirus showed distinct signs of
viral myocarditis, as severe cardiac muscle damage and massive
lymphocytic infiltration were observed (Figure 5C). On the other
hand, mice treated with AV reovirus showed no symptoms of heart
damage by 25 days post-viral treatment. Immunohistochemical
analysis of heart tissue revealed an abundance of viral proteins in
mice treated with WT reovirus, whereas no viral proteins were
detected in the heart tissues of mice treated with AV reovirus
(Figure 5C). Taken together, WT reovirus not only infected tumour
sites and prevented tumour growth, but also systemically infected
Attenuated oncolytic reovirus with reduced toxicity
M Kim et al
294
British Journal of Cancer (2011) 104(2), 290–299 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sR1 ES
Mock Mock AV AV WT
104
103
102
R
e
o
-
F
I
T
C
 
i
n
t
e
n
s
i
t
y
101
100
0 500
Mock
R1 ES
D3 ES
14 R1 ES
WT
AV
D
12
5
4
MES1 ES
WT
AV
PBS
3
2
1
0
0 12 15 19 28 31 38 43
10
T
e
r
a
t
o
m
a
 
v
o
l
u
m
e
 
(
c
m
3
)
8
6
4
2
0
0 12
D reo AV reo WT reo
141719212426283133 Days
AV WT
500
Forward scatter
500 1000 1000 1000



D3 ES
WT
Figure 3 Cytopathogenicity of AV and WT reovirus on embryonic stem cells. (A) Pluripotent murine ESCs (R1 and D3) were infected with WT or AV
reovirus (MOI of 20). At 48 hpi, cell lysates were prepared and viral proteins (l, m and s) were detected by immunoblotting using reovirus antiserum (left
panel). Alternatively, cells were fixed/permeablized for FACS analysis at 48h post-infection and reovirus antiserum and secondary FITC antiserum were used
to detect the presence of reovirus proteins (right panel). (B) At 48 hpi, viral cytopathic effects were also photographed. (C) Severe combined
immunodeficiency mice received a single implantation of murine R1 (left panel) or MES1 (right panel) ESCs. At 12 days following implantation, teratomas
were intratumourally injected with WT or AV reoviruses (10
7 PFU per mouse; n¼3–5) or D Reo (Dead, UV-inactivated reovirus) or PBS and teratoma
growth was monitored for 21–70 days post-infection. Mice treated with WT reovirus were killed at 18–19 days post-infection because of the formation of
viral-induced myocarditis. (D) Photographs of representative R1 teratomas were taken 21 days after implantation (9 days post-infection).
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shost heart tissues. In contrast, AV reovirus retained efficient
oncolytic activity and caused less damage to healthy tissue in the
SCID mouse model.
DISCUSSION
As a naturally oncolytic virus, reovirus preferentially infects and
kills cancer cells with active Ras signalling or defective tumour
suppressors, making the virus a promising anti-cancer agent
(Coffey et al, 1998; Kim et al, 2010). In light of this finding, reovirus
has been tested in a wide range of cancers both in vitro and in vivo,
and is currently undergoing phase I, II and III clinical trials (Strong
et al, 1998; Duursma and Agami, 2003; Norman et al, 2004).
Although only mild toxicity has been reported in patients
(Thirukkumaran and Morris, 2009), animal models have indicated
that reovirus pathogenesis is not entirely restricted to cancer cells,
as the virus is capable of inducing haemorrhage, fibrosis, hepatitis,
pancreatitis, necrotising encephalitis and myocarditis in mice
(Sabin, 1959; Baty and Sherry, 1993; Richardson et al, 1994; Mann
et al, 2002; Loken et al, 2004). Furthermore, as these viruses are
delivered to tumour-bearing hosts by intravenous injection, normal
tissues, including stem cells and their developmental potential, may
be subject to viral challenge (Heggie and Gaddis, 1979; Priscott,
1983). It may therefore be useful to identify and generate a
modified reovirus that exhibits enhanced safety while maintaining
its oncolytic potential, thereby providing a potentially higher dose
or treatment number.
During our study of reovirus resistance in Ras-transformed
human fibrosarcoma HT1080 cells (Kim et al, 2007), we
serendipitously isolated an S1 attenuated reovirus variant from
persistently infected HTR1 cells (Figure 1). As is the case with
reovirus mutants derived from persistent infections, the AV
reovirus arising from the HTR1 culture displayed significant
genetic alterations. Genomic sequence analysis revealed several
mutations in the S1 gene segment, with the most significant
resulting in a nonsense mutation at nucleotide 763 and a truncated
s1 protein (Table 1 and Figure 2). It is noteworthy that the
sequence that was established for the AV reovirus, including the
premature stop codon in the S1 gene, has remained stable for over
3 years of culture, suggesting a highly stable coadaptation between
virus and host cell in the HTR1 culture (Kim et al, 2007).
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Figure 4 AV reovirus retains its oncolytic activity in vitro.( A) HT1080, L929 and HCT116 cells were either mock infected or infected with WT or AV
reovirus at an MOI of 40. At 48h post-infection, viral cytopathic effects were photographed. (B) HT1080, L929 and HCT116 cells grown to 70% confluency
were infected with WT or AV reovirus at a MOI of 20. Cell lysates were collected at the indicated timepoints and using equal loading, were analysed by
immunoblotting with polyclonal reovirus antiserum.
Figure 5 AV reovirus remains oncolytic in vivo and shows reduced toxicity. (A) HTR1, Raji PI and CA46 PI cells were injected into the left flanks of SCID
mice, which were photographed after 3–4 weeks and as morbidity developed. All Raji PI- and CA46 PI- treated mice developed black tails at 22–25 days
post-injection (center and right panels) and were killed shortly thereafter; whereas HTR1-treated mice displayed no signs of distress after 4 weeks (left
panel) and only began to develop black tails at 3–7 months post-injection. (B) Severe combined immunodeficiency mice received single implantations of
5 10
6 HCT116 colon carcinoma or HT1080 fibrosarcoma cells. At 11 days after implantation, palpable tumours were injected with WT, AV or
UV-inactivated (Dead; D) reoviruses at 10
7 PFU/tumour and tumour growth was followed up to 34 days post-implantation. WT reovirus was reinjected
23 days post-implantation and AV reovirus was reinjected 23 and 27 days post-implantation. (C) Histological comparison of HCT116 and HT1080 tumours
and heart tissue from SCID mice treated with reoviruses (WT, AV and D reovirus as above). Paraffin sections of reovirus-treated tumours (24 days post-
infection) were analysed by indirect immunohistochemical staining using reovirus antiserum; brown staining represents reoviral antigen positive regions
(upper panels). Paraffin sections of heart tissue from reovirus-injected mice (23 days post-infection) were analysed by H&E (middle panels) and indirect
immunohistochemical staining (lower panels) using reovirus antiserum. Extensive necrotic lesions (arrows) and massive lymphocyte infiltration were
observed in heart tissue from WT reovirus-infected mice, but not AV virus-treated mice (middle panel). Wild-type reovirus infected mice also showed
reoviral antigen-positive regions (arrows; lower panel); sections were counter-stained with methyl green.
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sGenetic reassortment studies have shown that the S1 gene
segment of reovirus T3D is the major determinant in reovirus-
induced pathogenesis (Weiner et al, 1977, 1980; Dichter and Weiner,
1984; Haller et al, 1995), with the s1 protein having a critical role in
reovirus-mediated apoptosis (Tyler et al, 1995; Connolly et al, 2001).
Despite the S1 modification, AV reovirus retained robust
viral replication in various cancer cell types, including those
with an activated Ras signalling pathway (Figure 4). Although the
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sAV virus displayed a significantly reduced, but not abolished,
apoptotic potential in vitro (Figure 4), it was able to reduce
tumour size in vivo to levels comparable with that of the WT virus
(Figure 5). In terms of its pathogenesis in normal cells, AV reovirus
consistently caused less damage to normal cells than its
WT counterpart. The virus only minimally infected ESCs in vitro
and did not adversely affect ECS development in vivo (Figure 3).
Furthermore, even with multiple injections in SCID mice, AV
reovirus did not induce black tail syndrome or myocarditis
(Figure 5). Taken as a whole, AV reovirus pathogenesis is limited
to cancer cells and this oncolytic specificity is even greater than the
WT virus when taking into account the reduced damage by AV
virus to normal cells.
Unlike the AV reovirus from HTR1, reoviruses from Raji PI and
CA46 PI, both possess full-length s1 and caused severe viral
pathogenesis comparable with that of WT reovirus (Loken et al,
2004). This was consistent with the notion that the reduced viral
pathogenesis seen with AV reovirus was strongly associated with the
S1 gene attenuation acquired during persistent reovirus infection of
the HT1080 fibrosarcoma cells, but not necessarily arising during
the persistent infection of other cell types. As AV reovirus also
contained several mutations in the S4 gene (S4 mutations are also
present in CA46 PI- and Raji PI-derived viruses), which encodes one
of the major outer capsid proteins, we cannot rule out the possibility
that these mutations (and those that may be present in other gene
segments) also have a role in virus attenuation. However, in view of
the well-documented role of the S1 gene in reovirus pathogenesis,
we favour the idea that the nonsense mutation in S1 likely has a
major, if not the sole, role in AV virus attenuation.
With its significantly reduced viral pathogenic potential and
retained ability to display strong oncolytic activity in vivo,A V
reovirus may deserve consideration as an alternative therapeutic
agent for various types of tumours in immunosuppressed patients.
These findings may also serve as a starting point for optimising
reovirus’ potential as a cancer therapeutic through the use of
the newly developed reverse genetics system for dsRNA viruses
(Kobayashi et al, 2007).
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